Clinical investigation of recombinant and human plasma-derived factor VIII products

Current effective version

PDF iconRevision 2 - Adopted guideline

Revision 2 enters into effect 01/02/2019 - see below

Reference number EMA/CHMP/BPWP/144533/2009 Rev. 2
Published 13/08/2018
Effective from 01/02/2019
Keywords Recombinant factor VIII, plasma-derived factor VIII, efficacy, safety, immunogenicity, inhibitor, potency assays
Description This document covers clinical investigations to be conducted pre- and post-marketing authorisation for recombinant or human plasma-derived factor VIII products that are intended to use in the treatment and prevention of bleeding in patients with haemophilia A.


Document history

Revision 2

 

PDF iconAdopted guideline

 


PDF iconDraft guideline

 

PDF iconConcept paper

Published: 13/08/2018
Effective from: 01/02/2019

 


Published: 30/10/2017

 

Published: 01/08/2016

Revision 1

Current version

PDF iconAdopted guideline

 

PDF iconDraft guideline

In operation: 01/05/2016–present

 

Published: 01/06/2015

First version

 

PDF iconAdopted guideline

 

PDF iconDraft guideline

In operation: 01/02/2012–01/05/2016

 

Published: 23/07/2009

Superseded document

 

PDF iconDraft guideline

 

PDF iconConcept paper

 

PDF iconAdopted guideline

Published: 19/07/2007

 

Published: 15/12/2004

 

In operation: 01/04/2001–23/07/2009

Superseded document

 

PDF iconDraft guideline

 

PDF iconConcept paper

 

PDF iconAdopted guideline

Published: 19/07/2007

 

Published: 15/12/2004

 

In operation: 01/04/2001–23/07/2009


Related content


How useful was this page?

Add your rating